ImageneBio, Inc. 8-K

What Happened
ImageneBio, Inc. announced that Erin Butler, the Company’s Senior Vice President, Finance & Administration and Principal Accounting Officer, will mutually separate from the company effective March 20, 2026. The company expects to enter a separation agreement under which Butler will receive severance benefits under her existing Severance Rights Agreement dated October 21, 2024. Effective March 20, 2026, the board appointed Bob Lally as the Company’s Principal Accounting Officer.

Key Details

• Separation effective date: March 20, 2026.
• Severance: Butler to receive benefits under her Severance Rights Agreement (dated Oct 21, 2024; filed as Exhibit 10.16 to the Form 8‑K on July 29, 2025).
• Successor: Bob Lally (age 63), Senior Vice President, Finance & Operations since July 2025, appointed Principal Accounting Officer effective March 20, 2026.
• Background on Lally: previously SVP Finance & Operations at predecessor Ikena Oncology (Dec 2022–July 2025); roles at Prevail Therapeutics (VP Finance, Chief Operating Officer) and Arsanis (Executive Director, Finance and Controller); B.S. in Finance from UMass Lowell.
• No new material plan, contract or arrangement was entered into with Lally in connection with his appointment; no family relationships or related‑party transactions requiring Item 404 disclosure.

Why It Matters
A Principal Accounting Officer is a key finance role involved in the company’s accounting, financial reporting and internal controls. Investors should note the leadership change and that the company promoted an experienced internal executive as successor. The filing discloses a planned separation and existing severance treatment for Butler but does not quantify any cash impact; no new compensation agreement for Lally was reported.